ViiV Healthcare (United States)

ViiV Healthcare is a specialist HIV pharmaceutical company owned by GlaxoSmithKline, Pfizer, and Shionogi. The company develops and commercializes innovative HIV treatments including Dovato (dolutegravir/lamivudine), Triumeq, Tivicay, and Cabenuva (cabotegravir/rilpivirine), the first long-acting injectable HIV regimen. ViiV’s dedicated focus on HIV/AIDS advances treatment and prevention worldwide.